Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05706623
Other study ID # TA799-015
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 30, 2023
Est. completion date April 4, 2023

Study information

Verified date July 2023
Source VectivBio AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to assess the PK of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single SC dose administration.


Description:

A two stage design, open label, multi-center, non-randomized trial to evaluate the the safety and tolerability of a single subcutaneous dose of 5 mg apraglutide in subjects with varying degrees of hepatic function. The hepatic function will estimated with the Child-Pugh classification. Part 1: 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects with normal hepatic function (Cohort 2). Part 2: 8 subjects with mild hepatic impairment (Cohort 3) and 8 subjects with normal hepatic function (from Cohort 2 where possible and additional subject). Part 2 will be conducted only if the geometric mean ratio (GMR) of AUCinf or AUClast for the moderate hepatic impairment group compared to the control group is ≥2.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date April 4, 2023
Est. primary completion date April 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: All Participants: - Age between 18 and 75 years inclusive - Subjects who are willing and able to comply with the study procedures - Subjects able to understand and willing to sign the informed consent - Body mass index (BMI) of =18 to =35 kg/m2; and a total body weight of >50 kg (110 lb). - Women of childbearing potential (WOCBP) on highly effective method of contraception during the trial and for 1 month after the end of trial (EOT) visit. Sterilized or infertile or postmenopausal females. - Male subjects with a female partner of childbearing potential: highly effective methods of contraception and no sperm donation during the trial and for 1 month after (EOT) visit. Participants with impaired hepatic function: - Confirmed and documented diagnosis of cirrhosis - Moderate liver disease (Child-Pugh B): clinically stable for at least 1 month prior to screening - Mild liver disease (Child-Pugh A): clinically stable for at least 1 month prior to screening Exclusion Criteria: - History of clinically significant GI, bronchopulmonary, neurological, cardiovascular, endocrine, or allergic disease - Known hypersensitivity to the investigational medicinal product (IMP), any of their excipients or drugs of the same class - If capable of reproduction, unwilling to use an effective form of contraception - If a female of child-bearing potential, a positive urine/blood pregnancy test - Breast-feeding women - Positive urine/blood test for alcohol and drugs of abuse at Screening and on Day-1 - Use of prohibited medications or herbal remedies - Known presence or history of intestinal polyps - Known presence or history of any type of cancer - Pancreatic events such as acute pancreatitis, pancreatic duct stenosis, pancreas infection, and increased blood amylase and lipase (>2.0-5.0×upper limit of normal range) - Participation in an investigational drug or device study within 30 days prior to Screening - Donation of blood over 500 mL within 2 months prior to Screening - Heavy use of tobacco products (i.e., smokes more than 10 cigarettes per day) - Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial - Any intercurrent clinically significant illness in the previous 28 days before Day 1 of this study - Positive blood screen for human immunodeficiency virus (HIV) antigen/antibody combo, hepatitis A (HAV), hepatitis B surface antigen (HBsAgB), or hepatitis C virus (HCV) - Unwillingness or inability to comply with the study protocol for any other reason

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apraglutide
Single dose of apraglutide 5mg.

Locations

Country Name City State
Germany APEX Münich
Slovakia Summit Clinical Research Bratislava

Sponsors (1)

Lead Sponsor Collaborator
VectivBio AG

Countries where clinical trial is conducted

Germany,  Slovakia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma apraglutide primary PK parameter: AUCinf or AUClast Area under the curve to infinity (AUCinf) or area under the curve from time zero to the last quantifiable concentration (AUClast) if AUCinf cannot be reliably estimated 0 to 312 hours
Primary Plasma apraglutide primary PK parameter: AUC0-168h Area under the curve from time zero to 168 hours after apraglutide administration (AUC0-168h) 0 to 168 hours
Primary Maximum observed plasma concentration (Cmax) 0 to 168 hours
Secondary Time of maximum plasma concentration (tmax) 0 to 168 hours
Secondary Apparent clearance after extravascular administration (CL/F) 0 to 168 hours
Secondary Apparent volume of distribution after extravascular administration (Vz/F) 0 to 168 hours
Secondary Terminal elimination rate constant (?z) 0 to 168 hours
Secondary Terminal half-life (t½) 0 to 168 hours
Secondary Incidence, nature,and severity of adverse events (AE) with apraglutide Baseline to Day 16
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05009680 - A Single and Repeat Dose Trial in Participants With Hepatic Impairment Phase 1/Phase 2
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Terminated NCT05517226 - Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment Phase 1
Completed NCT03983161 - A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment Phase 1
Completed NCT04546789 - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK Phase 1
Completed NCT03282513 - A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function Phase 1
Recruiting NCT05976321 - A Study of TAK-279 in Adults With or Without Liver Damage Phase 1
Completed NCT04473664 - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment Phase 1
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Completed NCT03290443 - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. Phase 1
Completed NCT02244827 - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment Phase 1
Completed NCT02245243 - Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment Phase 1
Completed NCT02004587 - Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers Phase 1
Completed NCT01621633 - A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers Phase 2
Completed NCT01493869 - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects Phase 1
Completed NCT04482270 - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function Phase 1
Completed NCT02115347 - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) Phase 1
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT06161259 - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment Phase 1
Completed NCT05409911 - A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants Phase 1